Datong

Researchers are evaluating the safety, tolerability, pharmacokinetics, and immune response of a drug called B1344 in patients diagnosed with Nonalcoholic Fatty Liver Disease (NAFLD). This randomized, double-blind, multicenter, placebo-controlled Phase Ib trial also aims to gather early evidence on the potential effectiveness of B1344 as a treatment for Nonalcoholic Steatohepatitis (NASH), a severe form of NAFLD. Participants will receive multiple doses of either B1344 or a placebo through subcutaneous injections. The trial involves escalating doses to assess safety and drug behavior in the body. This controlled setup helps compare responses between the active treatment and placebo groups over the course of the study. Throughout the 113-day trial, participants will undergo regular monitoring for side effects and serious adverse events. Researchers will collect data on how the drug is processed by the body and its immune effects. Participants will also have assessments including MRI scans and blood tests. The study requires signing informed consent and adherence to trial procedures to ensure comprehensive safety and efficacy observations.

The study population are patients with acute anterior circulation large vessel occlusion stroke and planned to undergo endovascular treatment. All participants are randomly assigned in a 1:1 ratio to the tocilizumab group or the placebo group. In tocilizumab group, participants will receive tocilizumab combined endovascular treatment. And in placebo group, participants will receive placebo combined endovascular treatment. All participants will be visited immediately postoperatively, at 24 hours, 7 days, and 90 days after randomization.

Researchers are evaluating the effectiveness and safety of the KPCXM18 injection at different doses for treating acute ischemic stroke in this multicenter, randomized, double-blind, placebo-controlled phase 2 trial. The study aims to determine how well the injection works and to explore its safety profile, including population pharmacokinetic characteristics, to support future phase 3 studies. Participants will be randomly assigned to one of three groups: a low-dose KPCXM18 injection group receiving 60 mg intravenously twice daily, a high-dose group receiving 100 mg intravenously twice daily, or a placebo group receiving a matching intravenous infusion. Treatments will be given every 122 hours continuously for 122 days to assess dose-related effects. During the study, participants will undergo assessments including the Modified Rankin Scale at day 90 to measure recovery. Researchers will monitor safety and efficacy throughout the treatment and follow-up periods. The total number of participants is planned to be 300, with 100 in each group, all aged between 18 and 80 years old who have experienced acute ischemic stroke within 12 hours of symptom onset.

Researchers are conducting a phase II clinical trial to evaluate the safety, tolerability, and preliminary effectiveness of JS207 in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression after platinum-based chemotherapy and immunotherapy. This study focuses on patients with locally advanced or metastatic NSCLC that cannot be treated with surgery or radical radiochemotherapy. The goal is to understand how JS207 performs in this group who have limited treatment options. Participants receive one of several treatment combinations: JS207 injection alone at 10mg/kg or other dosages; JS207 combined with docetaxel at 75mg/m2 every three weeks; or JS207 combined with JS004 injection at 200mg every three weeks. These treatments are given in cycles spaced three weeks apart, and the study monitors their effects over time. During the trial, researchers will assess the objective response rate over 1.5 years to measure treatment effectiveness. Participants will undergo regular evaluations to monitor safety and tolerability. The study includes adults aged 18 to 75 years, and various assessments will be conducted to track disease status and adverse effects throughout the treatment period.

Researchers are evaluating the safety and effectiveness of JS107 compared to investigator-selected therapies for patients with advanced gastric or gastroesophageal junction adenocarcinoma that is positive for CLDN18.2 and negative for HER2. This Phase III, multicenter, randomized, controlled, open-label study focuses on patients who have already received at least one prior systemic treatment, including fluorouracil and platinum, and have disease progression. The main goals are to measure progression-free survival and overall survival. Participants will be randomly assigned to receive either JS107 or one of the investigator's chosen therapies, which may include irinotecan, paclitaxel, or docetaxel. Treatment will continue until disease progression confirmed by blinded independent central review, death, loss to follow-up, withdrawal of consent, or study termination by the sponsor. Both groups will follow their assigned treatment schedules throughout the study. During the study, patients will undergo regular assessments to monitor treatment response and safety. Researchers will use imaging according to RECIST v1.1 criteria to measure tumor changes and track progression-free survival up to 2 years, as well as overall survival for up to 5 years. Safety and tolerability will be closely observed, and participants will be followed for survival outcomes throughout the study duration.

This research investigates how weight loss through a diet management mobile app and an intelligent weight scale affects cardiovascular health in obese patients with heart failure. The study focuses on patients with heart failure with reduced ejection fraction and aims to see if these tools can reduce death rates, hospital stays related to heart failure, and improve frailty and quality of life. The trial addresses a gap where current heart failure guidelines recognize obesity as a risk but lack effective interventions for this group. Participants are randomly assigned to one of two groups: one group uses a fully functional diet management app and intelligent weight scale designed to support weight loss in obese heart failure patients, while the other group uses limited-function versions of the app and scale as a comparison. Both groups use the app at every meal and the scale daily for 12 months. The trial is a multicenter, single-blind randomized controlled study. During the study, participants will visit the clinic after 12 months for checkups. Researchers will collect data on a composite cardiovascular outcome, including all-cause mortality and hospitalizations related to heart failure, tracked over one year. Adherence to app and scale use is monitored through the mobile application. The study measures the impact on heart failure frailty, quality of life, and overall cardiovascular outcomes over the trial period.